An observational study in Head and Neck Cancer, Skull Base--Cancer and Brain Cancer, sponsored by CNAO National Center of Oncological Hadrontherapy. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-06.
Sponsored by CNAO National Center of Oncological Hadrontherapy · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 134 studies in Head and Neck Neoplasms with a site in Italy — 42 open to participants now, 56 under way, 6 of them phase 3. Head and Neck Neoplasms · Italy.
Among the 134 studies in Head and Neck Neoplasms with a site in Italy, this one is the 20th largest by planned enrollment of the 37 observational ones that give a count, is one of 14 that started in 2023, is one of 37 observational ones, reaches primary completion later than 11 of the 55 other live ones, and was the 91st registered.
2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.
Browse Head and Neck Neoplasms studies →42 of the 134 studies in Head and Neck Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Istituto Clinico Humanitas · Sites in Italy
Ages 18+
University of Turin, Italy · Sites in Italy
Ages 18+
European Institute of Oncology · Sites in Italy
Ages 18–99
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Sites in Italy
Ages 18+
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
134 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 44 · Phase 3 29
First in 1992; this study’s year is marked. 14 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 100 across 506 observational studies indexed under Head and Neck Neoplasms.
Median enrollment 160 across the 97 interventional studies, 200 across the 37 observational. Of the 65 that completed or were terminated, 28 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 134 have an industry lead sponsor. The 10 most frequent:
CNAO National Center of Oncological Hadrontherapy is the lead sponsor of 11 studies on the registry; 8 are open to participants now.
CNAO National Center of Oncological Hadrontherapy has 3 studies filed under Head and Neck Neoplasms — fewer than ten, so there is no comparison to draw.
11 of the studies in Head and Neck Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT06809673Ospedale Policlinico San MartinoPA.RI.GE. Study. The Prognostic Role of Inflammatory Circulating Biomarkers in HNSCC: a Prospective Multicentric Trial | 2026-12-31 |
| NCT07508319European Institute of OncologyRole of the Immune System in Preventing Laryngeal Cancer | 2026-12-31 |
| NCT06344208European Institute of OncologyPredicting Toxicity in Elderly Patients With Head and Neck Cancer | 2026-12-31 |
| NCT07448727University of Rome Tor VergataImpact of Early Response to First-line Anti-PD-1 Monotherapy in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma, Assessed by 18F-FDG PET/CT | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 134 studies in Head and Neck Neoplasms with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Quality of Life of patients treated with hadrontherapy is still limited. Two cohorts are established, they will be receiving specific standardized questionnaires to be evalutaed in their results.
Since 2011, CNAO has been treating patients suffering from solid tumors with particle therapy (both protons and carbon ions). Hadrontherapy improves outcome of radioresistant tumors which normally do not benefit from conventional radiotherapy. The treated population is highly heterogenous in term of tumor site, histotype, treatment fields and doses however its common anatomical origin justifies a unified approach in evaluating a QoL in this setting. QoL of patients suffering from these tumors have been poorly investigated and there are still few studies on patient reported outcomes (PROs) and QoL following hadrontherapy. In this context, therefore, there is a need to generate data by designing distinct cohort studies, conceived within a single protocol, that will gather quality of life data by means of standardized questionnaires of patients along their oncological history. Thanks to this protocol design, the investigator will be facilitated, in the future, in adding new cohorts pending a study protocol amendment and ethical approval.
The patients from cohort A will be selected and invited to participate in the study when evaluated for standard of care follow-up which is taking place in telemedicine modality through a digital meeting organized by the staff.
Patients from Cohort B with indication of hadrontherapy in radical setting will be consecutively enrolled at baseline (during CT simulation procedure or at the first session of RT).
Cohort A ("survivors"):
Inclusion Criteria
Exclusion Criteria:
Cohort B:
Inclusion Criteria:
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
about 80 patients with at least a 5 year follow up with head and neck, skull base and brain tumors and no evidence of progressive disease.
Other: questionnaires administration
100 patients with histological and/or radiological diagnosis of head and neck tumors enrolled at baseline
Other: questionnaires administration
Enrolled people will be requested to fill in questionnaires. Cohort A affected by head and neck cancer: SF-12, EORTC QLQ-C30, EORTC QLQ-H\&N43, HADS, Brief COPE, BRCS. Cohort A affected by skull base/brain cancer: SF-12, EORTC QLQ-BN20, HADS, Brief COPE, BRCS. Cohort B will receive: EORTC QLQ-C30, BRCS, PROFFIT, SF-12, EORTC QLQ-H\&N43.
investigate relation between quality of life and several socio- psycho- variables
quality of life in subjects treated with curative hadrontherapy investigated by global score according to Short-form-12-health-survey-questionnaire (SF-12) and compared to healthy population
Time frame: 5 years follow uo after hadrontherapy
quality of life related also to psychological variables, socio-cognitive factors, resilience
quality of life in subjects treated with curative hadrontherapy investigated by global score according to EORTC QLQ-C30
Time frame: before treatment and after 1 year from treatment completion
Started Mar 2023 (actual). Primary completion is estimated for Sep 2025, 29 months after the start.
Of 216 non-industry observational studies under Head and Neck Neoplasms, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 144. This study's planned 29 months is below that.
Counting every sponsor, half of 238 studies reached it within 69 months; a quarter within 29 and three quarters within 144.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CNAO National Center of Oncological Hadrontherapy